Literature DB >> 21888442

Drug treatment of hypertensive crisis in children.

Christopher A Thomas1.   

Abstract

Hypertensive crisis is a relatively rare event and is associated with significant morbidity and mortality in adults and pediatric patients alike. Rapid, safe, and effective treatment is imperative to alleviate immediate presenting clinical symptoms, prevent devastating morbidity, preserve long-term quality of life, and prevent mortality. Many medications in the hypertensive crisis arsenal have been used for nearly half a century. Nearly all treatment options have been utilized in children for decades, yet reliable data and sound clinical literature remain elusive. Every agent considered to be a first-line, second-line, or adjunctive option has yet to be evaluated in a randomized controlled trial in pediatric patients. With a paucity of clinical data to form evidence-based decisions, the clinician must rely entirely on the extrapolation from adult data and small retrospective studies, case series, and case reports of medication use in pediatric patients. Although more research in the treatment of pediatric hypertensive crisis is desperately needed, current practice demands a sharp knowledge of the pediatric clinical literature and pharmacology in this area as an essential tool to consistently improve patient outcomes with respect to morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888442     DOI: 10.2165/11592130-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  69 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

Review 2.  Emergency management of pediatric hypertension.

Authors:  Srinivasan Suresh; Prashant Mahajan; Deepak Kamat
Journal:  Clin Pediatr (Phila)       Date:  2005 Nov-Dec       Impact factor: 1.168

Review 3.  Advances in the pathogenesis and management of hypertensive crisis.

Authors:  Hiren P Patel; Mark Mitsnefes
Journal:  Curr Opin Pediatr       Date:  2005-04       Impact factor: 2.856

4.  Cardiovascular and antiarrhythmic effects of esmolol in children.

Authors:  D L Trippel; D B Wiest; P C Gillette
Journal:  J Pediatr       Date:  1991-07       Impact factor: 4.406

5.  Dosage of nifedipine in hypertensive crises of infants and children.

Authors:  J Lopez-Herce; P Dorao; P de la Oliva; M A Delgado; M C Martinez; F Ruza
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

6.  Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels.

Authors:  L Bang; J E Nielsen-Kudsk; N Gruhn; S Trautner; S A Theilgaard; S P Olesen; S Boesgaard; J Aldershvile
Journal:  Eur J Pharmacol       Date:  1998-11-13       Impact factor: 4.432

7.  Sodium thiosulphate decreases blood cyanide concentrations after the infusion of sodium nitroprusside.

Authors:  P V Cole; C J Vesey
Journal:  Br J Anaesth       Date:  1987-05       Impact factor: 9.166

8.  Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension.

Authors:  Rogier V Immink; Bert-Jan H van den Born; Gert A van Montfrans; Yu-Sok Kim; Markus W Hollmann; Johannes J van Lieshout
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

9.  Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.

Authors:  B F Cuneo; V R Zales; P C Blahunka; D W Benson
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

Review 10.  Management of hypertensive crises.

Authors:  Carlos Feldstein
Journal:  Am J Ther       Date:  2007 Mar-Apr       Impact factor: 2.688

View more
  2 in total

Review 1.  Pediatric hypertensive emergencies.

Authors:  Rossana Baracco; Tej K Mattoo
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 2.  Therapy of acute hypertension in hospitalized children and adolescents.

Authors:  Tennille N Webb; Ibrahim F Shatat; Yosuke Miyashita
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.